|Bid||92.37 x 60000|
|Ask||92.79 x 60000|
|Day's Range||90.51 - 92.17|
|52 Week Range||57.79 - 100.00|
|PE Ratio (TTM)||27.90|
|Forward Dividend & Yield||3.08 (3.42%)|
|1y Target Est||N/A|
These healthcare stocks ranked among the 25 most popular stocks for hedge funds. Here's why they should be popular with regular investors too.
J&J (JNJ) receives an offer for its LifeScan unit from private firm, Platinum Equity. It has time until Jun 15 to accept the offer, failing which it will expire.
AstraZeneca, Bristol and Vertex are the likeliest targets of widespread mergers and acquisitions across the biopharma group.
Merck gains priority review for Keytruda in advanced cervical cancer, AbbVie's elagolix meets primary endpoint in second phase III study.
Zacks Market Edge Highlights: Scotts Miracle-Gro, GW Pharmaceuticals, Innovative Industrial Properties and AbbVie
Visa, AbbVie and Tencent are in different fields but have very similar stock charts, reflecting the action of the major averages.
AbbVie (ABBV) and partner Neurocrine Biosciences announce that the second of the two pivotal phase III studies evaluating elagolix, met the primary endpoint for treating women with uterine fibroids.
A pharmaceutical stock and a consumer goods giant make up two of these three attractive investments for those approaching retirement.
The size of AbbVie Inc (NYSE:ABBV), a US$182.17B large-cap, often attracts investors seeking a reliable investment in the stock market. Big corporations are much sought after by risk-averse investors whoRead More...
The FDA is reviewing whether a type of brain inflammation called encephalitis linked to Biogen and AbbVie’s MS drug Zinbryta was a result of a known side effect of the therapy or has another cause, a FDA ...
The biotech sector was in focus last week with these stories - FDA's acceptance of Regeneron's Dupixent's application for asthma, Biogen and partner AbbVie's decision to withdraw multiple sclerosis drug among others.
The Food and Drug Administration is reviewing whether a type of brain inflammation called encephalitis connected to Biogen Inc. and AbbVie Inc.'s multiple sclerosis drug Zinbryta was a result of known ...
Europe's medicines regulator recommended the immediate suspension and recall of Biogen Inc and AbbVie Inc's multiple sclerosis drug Zinbryta, following 12 reports of inflammation of the brain, three of which cases were fatal. Biogen and AbbVie withdrew the drug last week, after the European Medicines Agency (EMA) started an urgent review.
Senator Tina Smith wants some answers from a group of Big Pharma companies about how the new cash flowing from the corporate tax break will be spent.